The effect of direct photocoagulation combined with intravitreal injection of anti-VEGF agents for diabetic macular edema

The effect of direct photocoagulation combined with intravitreal injection of anti-VEGF agents for diabetic macular edema - Combination therapy of direct photocoagulation and anti-VEGF agents for diabetic macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035833

Enrollment

Registered

2019-02-11

Start date

2015-11-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic macular edema

Interventions

directphotocoagulation + anti-VEGF therapy The duration of additioanal photocoagulation is 6 months after initial injection og ranibizumab.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who had diabetic macular edema.

Exclusion criteria

Exclusion criteria: (1) focal/grid photocoagulation, PRP within the previous 12 months, (2) active intraocular inflammation or infection in either eye, (3) uncontrolled glaucoma in either eye, (4) previous treatment with the anti-angiogenic drug (5) a history of stroke, (6) a systolic blood pressure (BP) > 160 mm Hg or a diastolic BP > 100 mm Hg, or untreated hypertension.

Design outcomes

Primary

Measure	Time frame
retinal thickness, visual acuity	—

Countries

Japan

Contacts

Public ContactYoshihiro Takamura

University of Fukui Department of Ophthalmology

ytakamura@hotmail.com+81-776-61-8403

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026